Good evening :)
$
₹
Ascentage Pharma Group International

Ascentage Pharma Group International

AAPG

NASDAQ
Asset Logo

Ascentage Pharma Group International

AAPG

NASDAQ
$15.0611.75% (+1.58)
$
₹
$15.0611.75% (+1.58)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $1.3B the stock is ranked 2536

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

15.13
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.25
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-228.54%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 11 analysts reports

Buy
11 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+230.12%

Earnings Growth

+70.33%

Rev. Growth

+21.33%

See Detailed Forecast

Company Profile

Company Profile

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

2026
Current$13.48Baseline
Analyst Target - 1 year
Target$44.5+230.12%

All values in $

20232024202520262027$21.34$30.54$39.75Target+230.12%
2026
Current$13.48Baseline
Analyst Target - 1 year
Target$44.5+230.12%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 21.33% growth, versus a trailing 3-year CAGR of 38.61%.

2025
Current$558.47Baseline
Forecast for Dec 2026
High$879.38+57.46%
Average$677.61+21.33%
Low$614.08+9.96%

All values in $ Million

20212022202320242025202627.91209.71221.98980.65558.47Low+9.96%Average+21.33%High+57.46%
2025
Current$558.47Baseline
Forecast for Dec 2026
High$879.38+57.46%
Average$677.61+21.33%
Low$614.08+9.96%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-3.97Baseline
Forecast for Dec 2026
High$-0.57+85.64%
Average$-1.18+70.33%
Low$-2.38+40.05%

All values in $

20222023202420252026N/AN/AN/A-3.97Low+40.05%Average+70.33%High+85.64%
2025
Current$-3.97Baseline
Forecast for Dec 2026
High$-0.57+85.64%
Average$-1.18+70.33%
Low$-2.38+40.05%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

233.6
-590.7
334.1
-639.9
334.1
-639.9
298.8
-807.6
Q2 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q4 2025Q1 2026Q2 2026
Total Revenue79.28411.87823.7478.45156.90156.90233.69334.13334.13298.87
Net Income-523.2881.50163-284.21-568.43-568.43-590.76-639.95-639.95-807.67
Net Profit Margin-660.01%19.78%19.78%-362.28%-362.28%-362.28%-252.79%-191.52%-191.52%-270.23%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Ascentage Pharma Group International -15.13-
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare AAPG with any stock or ETF
Compare AAPG with any stock or ETF
Comparing from
AAPG
ABBV
AMGN
Loading...

Frequently asked questions

  1. Ascentage Pharma Group International (AAPG) share price today is $15.06 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $15.19 and a day low of $14.50.

  2. Ascentage Pharma Group International stock trades on NASDAQ under the ticker symbol AAPG.

  3. Ascentage Pharma Group International's market capitalization is $1.25B as of November 5, 2026 at 2:29 AM IST.

  4. Ascentage Pharma Group International's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Ascentage Pharma Group International's price-to-book (P/B) ratio is 15.13 as of November 5, 2026.

  6. Yes, You can buy Ascentage Pharma Group International shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Ascentage Pharma Group International shares in three steps: 1. Search Ascentage Pharma Group International on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Ascentage Pharma Group International trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Ascentage Pharma Group International (AAPG) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.6638 shares at the current price of $15.06.

Loading...